Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Quietly Acquires microRNA Company Actigenics ...

NEW YORK (GenomeWeb News) – Cepheid today acquired Actigenics for an undisclosed sum, the company said today.
 
Cepheid acquired the French company for its microRNA portfolio. Actigenics possesses both therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to out-license therapeutic applications of these microRNAs, the company said in a statement.
 
The microRNAs may potentially provide the basis for a broad range of proprietary markers for Cepheid in “cancer-specific markers, infection-specific markers, inflammation-specific
markers, and surrogate markers of complex regulatory mechanisms,” the company said.
 
Cepheid may also develop diagnostic tests associated with the therapeutic applications.
 
Financial details were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.